SOS Lab

464080 · KOSDAQ · ₩464080 · 에스오에스랩

₩8,380▼ ₩400 (4.56%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me

What brokers say about SOS Lab

No public broker reports on this company yet.

Calculated by JONBUR from publicly available broker reports. Reports belong to their publishers. Not financial advice. Includes brokers that publish research publicly; some brokers' reports are client-only and not included.

AI summary of public information

An AI summary of the public information on this company: filed financial statements, filings, prices and news headlines. It doesn't use broker reports; their targets and estimates are shown above.

SOS Lab is growing revenue and launching new LiDAR products, but it still posts large operating losses and carries heavy debt.

SOS Lab, a Korean LiDAR sensor maker, reported trailing twelve-month revenue of about ₩5.0B against an operating loss of about ₩18.2B for the period to H1 2026. Its 2025 revenue rose 23.3% to ₩6.1B, but net losses widened to ₩17.7B, and borrowings of about ₩49.9B exceed its ₩1.9B cash. Recent filings and news centre on new smart-infrastructure and autonomous driving LiDAR products and a partnership with Semunite.

What stands out

  • Trailing revenue is ₩5.0B, but operating margin is -361.7% and net margin is -388.4%, so losses are large relative to sales.
  • 2025 revenue grew 23.3% to ₩6.1B, yet operating losses were about ₩16.1B that year.
  • Liabilities are 391.8% of equity and trailing free cash flow was about -₩15.5B, which points to reliance on external funding.
  • Shares are at ₩9,060, down 8.5% over one month and 9.4% over one year, though up 11.2% over three months and well below the 52-week high of ₩28,700.
  • Recent news covers the ML-I LiDAR for smart infrastructure and a Semunite collaboration, but the data does not show revenue from these yet.
  • Foreign ownership rose from 1.2% to 2.1% over 60 days, while retail investors were net sellers over the last 20 days.

What to watch

  • The next quarterly and annual results, to see whether revenue growth is narrowing the operating loss.
  • The conversion price adjustment filed on 2026-10-12, which may relate to convertible securities and potential dilution; the data does not give details.
  • Whether the new products and the Semunite partnership produce disclosed contracts; the data does not give their size or timing.

Data as of Oct 21, 2026 · written Oct 22, 2026

This is not financial advice.

Also known as: SOS Lab / 에스오에스랩 / 464080 / KRX:464080

Source: KRX statistical information